SAN JOSE, Calif., May 7, 2012 /PRNewswire/ -- Ariosa Diagnostics, a molecular diagnostics company, today announced that the Harmony™ Prenatal Test will be available in the United States and Canada through Laboratory Corporation of America® Holdings (LabCorp®) and Integrated Genetics, a member of LabCorp's Specialty Testing Group. Harmony represents an innovative non-invasive test for detection of common fetal trisomies utilizing a directed approach to analyze cell-free DNA (cfDNA) in maternal blood. The Harmony Prenatal Test is currently available in selected locations and will be broadly available next month.
"Ariosa Diagnostics is very excited to announce the official launch of the Harmony Prenatal Test and the agreement with LabCorp, which helps us deliver on the promise of bringing an affordable and accessible prenatal testing option to pregnant women and their physicians," said Ken Song, MD, chief executive officer at Ariosa Diagnostics. "With enhanced test performance and simplicity, the Harmony Prenatal Test can be reliably incorporated into the management of pregnancies."
The Harmony Prenatal Test, which detects common fetal trisomies such as Trisomy 21 (associated with Down syndrome), will be offered through LabCorp and will be available at its 1,000+ patient service centers. The test is performed using a simple maternal blood draw taken at a doctor's office or patient service center, and provides the safety of screening tests with accuracy approaching that of invasive testing for common fetal trisomies. The test is available to pregnant women of at least 10 weeks gestational age with a single fetus conceived without the use of an egg donor.
"We are pleased to be able to offer this novel, non-invasive prenatal test," indicated Mark Brecher, MD, LabCorp's chief medical officer. "Ariosa Diagnostics' Harmony Prenatal Test adds another option to LabCorp's comprehensive prenatal testing menu."
"The Harmony Prenatal Test is an affordable, high-quality test that provides a new choice for women," said Dr. Song. "Together with LabCorp, we are committed to ensuring that the latest advances in prenatal testing are accessible to all healthcare providers and women."
About Ariosa Diagnostics (formerly Aria Diagnostics)
Ariosa Diagnostics, Inc. is a molecular diagnostics company committed to providing safe, highly accurate and affordable prenatal tests for maternal and fetal health. Led by an experienced team, Ariosa is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. Ariosa's simple blood test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.
The company began operations in 2010 and is headquartered in San Jose, Calif. For more information, visit www.ariosadx.com.
*Integrated Genetics is a business unit of Esoterix Genetic Laboratories, LLC, a wholly-owned subsidiary of Laboratory Corporation of America Holdings.
|SOURCE Ariosa Diagnostics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved